Home / Stocks / Shree Ganesh Remedies Ltd
SGRL

Shree Ganesh Remedies Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹616.05

Change

-4.3 (-0.69%)

Open

₹620.6

Prev. Close

₹620.35

Day High

₹620.6

Day Low

₹612.45

Volume Analysis

Traded

2,745

Delivered

1,720

Delivery %

62.66%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Promoter holding is rising
  • •Strong operating margin (28.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (19.7%)
  • •Strong 3-year revenue growth (30.5%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹628.44 ₹624.52 ₹620.29 ₹616.37 ₹612.14 ₹608.22 ₹603.99
Fibonacci ₹624.52 ₹621.41 ₹619.48 ₹616.37 ₹613.26 ₹611.33 ₹608.22
Camarilla ₹618.29 ₹617.54 ₹616.8 ₹616.37 ₹615.3 ₹614.56 ₹613.81

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-4.24%

1 Month

-5.16%

3 Months

+21.37%

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹106.53

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

12.13%

Net margin 13.04% × asset turnover 0.75x × equity multiplier 1.24x

Company Overview

Sector

Healthcare

Market Cap

₹798 Cr

P/E (TTM)

65.9

ROE

10.8%

Book Value

₹129.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Shree Ganesh Remedies Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Valuation (20/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (28.0%). Strong 3-year EPS growth (19.7%).

TopFund Score — Fundamentals Quality

66/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

99

Valuation

20

Cash Flow

60

Corporate Governance

66

Momentum

63

Institutional Ownership

40

Business Quality

72

Risk & Volatility

60

Liquidity

50

From Screener.in

  • +Company has reduced debt.
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Debtor days have increased from 80.8 to 109 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Audio recording of Shree Ganesh Remedies' earnings call held on November 14, 2026.

Shree Ganesh Remedies invites investors to Q2 and H1FY27 earnings call on 14 November 2026.

Shree Ganesh Remedies reported Q2/H1FY27 results; commenced commercial production of two intermediates and completed Block 7A.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2021 Dec 2021 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 17 21 37 25 32 27 24 25 30 21 33 14 23
Expenses + 13 15 20 17 21 17 15 17 21 14 22 11 19
Operating Profit 4 6 17 8 11 10 10 7 10 7 11 3 4
OPM % 26.22% 27.31% 45.38% 32.81% 34.98% 36.64% 40.44% 29.59% 31.73% 31.88% 34.28% 23.33% 16.92%
Other Income + 0 1 1 1 0 1 2 1 1 1 1 1 1
Interest 0 0 0 0 0 0 1 1 1 1 1 0 1
Depreciation 1 1 2 2 2 3 2 2 3 3 3 2 3
Profit before tax 4 6 16 6 9 8 9 5 7 4 9 2 2
Tax % 22.76% 25.4% 22.46% 26.7% 25.81% 27.89% 24.83% 25.0% 26.23% 22.36% 28.21% 27.45% 28.19%
Net Profit + 3 4 13 5 6 5 7 3 5 3 6 1 2
EPS in Rs 3 3 10 4 5 4 5 3 4 2 5 1 1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 47 59 — — — — -35 0 -6 -22 36 -42 -23

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 16 16 20 27 35 64 49 126 109 109 92
Expenses + 14 14 16 22 26 52 35 84 69 74 67
Operating Profit 2 2 4 5 9 13 14 42 39 35 25
OPM % 13.0% 12.0% 21.0% 19.0% 25.0% 20.0% 28.0% 33.0% 36.0% 32.0% 28.0%
Other Income + 0 0 0 2 1 4 2 3 4 3 4
Interest 0 0 0 0 0 1 0 1 2 4 3
Depreciation 1 1 1 1 1 2 3 6 10 10 10
Profit before tax 2 2 4 6 9 14 13 38 31 24 16
Tax % 33.0% 34.0% 33.0% 28.0% 28.0% 23.0% 25.0% 26.0% 26.0% 26.0% —
Net Profit + 1 1 3 5 6 10 10 28 23 18 12
EPS in Rs 1 1 3 4 5 9 8 23 18 14 9
Dividend Payout % 0.0% 0.0% 0.0% 19.0% 18.0% 13.0% 18.0% 2.0% 0.0% 0.0% —
Sales growth -10 -6 27 36 — 82 -23 — -14 1 -14

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 12 13 15 20 25 33 109 132 150 153
Borrowings + 0 0 0 2 1 4 36 38 31 26
Other Liabilities + 2 2 5 5 7 9 12 8 14 18
Total Liabilities 15 16 21 36 41 55 171 192 208 210
Fixed Assets + 4 4 4 6 14 20 81 95 105 102
CWIP 0 0 0 0 0 0 17 9 13 16
Investments 0 0 0 4 4 3 5 18 13 11
Other Assets + 11 11 17 25 23 32 69 70 78 81
Total Assets 15 16 21 36 41 55 171 192 208 210
Equity Capital 1 1 1 9 9 9 13 13 13 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -1 -2 2 -1 -5 5 3 30 31 24
Cash from Investing Activity + 1 1 0 -3 0 -3 -1 -33 -35 -9
Cash from Financing Activity + 0 0 0 8 0 0 -1 10 -1 -12
Net Cash Flow -1 0 2 4 -5 1 2 7 -6 3
Free Cash Flow -1 -2 2 0 -5 5 3 -1 7 7
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -58 -79 44 -18 -60 37 24 92 104 82

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 69.33% → 72.83%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 30.66% 30.67% 30.66% 29.5% 27.19% 27.2% 27.2% 27.19% 27.2% 27.16% 26.65% 26.17%
Promoters 69.33% 69.33% 69.33% 70.49% 72.8% 72.8% 72.8% 72.8% 72.8% 72.83% 72.83% 72.83%
FII 0.0% 0.0% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.0% 0.0% 0.0% 0.0%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.52% 0.99%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Shree Ganesh Remedies Ltd (this stock) 798 65.9 4.79 10.8%
Kilitch Drugs India Ltd 805 33.4 2.79 10.6%
Zim Laboratories Limited 756 365.0 2.59 1.59%
Gaudium Ivf N Women H L 740 32.0 4.55 24.6%
Health X Platform Limited 862 510.0 1.36 0.44%
Wanbury Limited 676 20.3 4.3 76.5%
Themis Medicare Ltd. 929 624.0 2.33 0.41%

Which Mutual Funds Hold Shree Ganesh Remedies Ltd?

Frequently Asked Questions about Shree Ganesh Remedies Ltd

Community Sentiment

What are other investors saying about Shree Ganesh Remedies Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.